07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: RNA polymerase II (Pol II) polypeptide A (POLR2A); epithelial cell adhesion molecule (EpCAM)

Cancer INDICATION: Cancer Cell culture, mouse and patient sample studies suggest antibody-drug conjugates (ADCs) incorporating the Pol II inhibitor α-amanitin could help treat cancers that are hemizygous for the POLR2A gene. In 195 colorectal cancer...
07:00 , May 7, 2015 |  BC Innovations  |  Translation in Brief

Less is more

A single copy deletion of RNA polymerase II in colorectal cancer makes the tumors 10 times more sensitive to Heidelberg Pharma's ADCs Heidelberg Pharma's collaborators at the University of Texas MD Anderson Cancer Center have...